AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia




AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia

PRESS RELEASE

AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA

• The combination treatment was well-tolerated, with no hematological toxicity and no dose limiting toxicity
• The fourth patient had a complex karyotype including a monosomy of chromosome 5 and TP53 mutation, and was in the third-line of treatment. He had a near complete response after 14 days of treatment with AB8939 at 21 mg/m² plus venetoclax
• This is the fourth patient responding to the combination from a total of 4 patients treated
• The partial response rate is 100% (4/4), including one patient in complete remission, one near complete response and 2 partial responses
• The results were obtained after the first cycle of treatment (14 days) in patients receiving third- or fourth-line treatment, two of whom had previously progressed on venetoclax in combination with other chemotherapies
• These four patients all have very difficult to treat cytogenetic profiles, including complex karyotype, TP53 mutation, NRAS mutation, monosomy 5 and MECOM-rearrangement, that typically have a poor prognosis due to their aggressive disease course and treatment resistance
• This diversity of responsive patients appears to corroborate the mechanism of action of AB8939, which is capable of destabilizing microtubules while evading multi-drug resistance and also targeting cancer stem cells without eliminating non tumoral stem cells
• These results corroborate the positioning of AB8939 in patients with adverse genetics, complex karyotypes, TP53 mutations, NRAS and KRAS mutations, monosomy 5 and 7, and MECOM-rearrangement, which represents the highest unmet medical need.

Paris, 07 January 2026, 6pm CET

AB Science SA (Euronext – FR0010557264 – AB) today provides an update on the Phase 1 study of the molecule AB8939 and the fourth consecutive response with the combination of AB8939 + venetoclax in patients with acute myeloid leukemia (AML) associated with a very unfavorable genetic profile.

The fourth patient received AB8939 (21.3 mg/m²) plus venetoclax for 14 days.

The patient had AML with a very negative risk profile,

• complex karyotype including a monosomy of chromosome 5 and also an identified TP53 mutation
• in third-line of treatment, having progressed after CPX-351 treatment and Citarine + Idarrubincine + Fludarabine (3+7) regimen.

Under the AB8939 + venetoclax combination, the patient achieved a partial response.

This fourth result is consistent with the responses previously reported on October 14, 2025, in the first three patients who received AB8939 + venetoclax.

Nicholas J. Short, MD, Associate Professor and Co-Lead of the Section of Developmental Therapeutics, Department of Leukemia, MD Anderson Cancer Center, said, “This new data is very encouraging, particularly considering the very adverse risk profile of this patient’s leukemia. These early efficacy and safety data suggest that AB8939 can be combined with venetoclax and could have significant activity in the highest-risk subtypes of AML. There is a strong interest in continuing the development of this combination in patients whose AML has high-risk features that are expected to lead to resistance to venetoclax + azacitidine.“

Professor Olivier Hermine, MD, President of the Scientific Committee of AB Science and member of the Académie des Sciences in France, said, “There is a strong rationale to combine AB8939 and venetoclax as both molecules have low hematologic toxicity and complementary mode of actions. These first results are supportive of this rationale.”

About AB8939

AB8939 is a drug candidate that targets (i) cancer cells by destabilizing microtubules (essential for cell division) and (ii) cancer stem cells by inhibiting ALDH1A1 and ALDH2 (enzymes essential for maintaining their physiological state and survival).

• AB8939 has shown in vitro activity in Ara-C (cytarabine, which is one of the standards of care) resistant patient cell lines, including adverse genetic MECOM and TP53 mutations.
• Analysis of cell lines responsive to AB8939 showed that AB8939 is effective in cell lines with TP53 mutations, MECOM, and complex karyotypes, whereas ARAC and azacitidine are not effective.
• AB8939 increased survival and had an additive effect in combination with venetoclax (another standard of care) in vivo in a MECOM-grafted PDX mouse model.
• AB8939 increased survival and had an additive effect in combination with Vidaza (azacitidine, another standard of care) in vivo in the MECOM PDX#C1005 mouse model of leukemia.
• AB8939 eradicated Leukemia Cancer Stem Cells in vivo in a human PDX AML mouse model, which is compatible with targeting stem cells via ALDH.

AB8939 is currently being evaluated in a Phase 1 clinical trial (study AB18001, NCT05211570) in patients with refractory and relapsed AML.

The Phase 1 clinical trial of AB8939 has completed its first two stages, which consisted of determining the maximum tolerated dose (MTD) after 3 and 14 consecutive days of monotherapy. In both cases, the MTD was 21.3 mg/m².

The third stage, currently underway, involves evaluating the combination of AB8939 and venetoclax. Three patients were evaluated at the first dose level (AB8939 14 days at a dose of 16 mg/m² + venetoclax 14 days). The current dose level evaluates (AB8939 14 days at a dose of 21.3 mg/m² + venetoclax 14 days)

Medical need in AML and AB8939 mechanism of action

Although several drugs have been registered for AML, 70% of patients still relapse and die, creating a persistent unmet medical need for effective treatments. Acute myeloid leukemia remains the most lethal form of leukemia in humans.

AML is a heterogeneous disease, and its outcome is highly dependent on genetic factors. TP53 mutation has a very poor prognosis, with a median overall survival (OS) of 5.5 months. NRAS and KRAS mutants have a poor prognosis, with a median OS of 12.1 months. MECOM also has a very poor prognosis in AML, with a median OS of 5.5 months in relapsed or refractory settings.

The challenge in AML is the recurrence of tumors due to a combination of two factors: the resistance of cancer cells to chemotherapy and relapse due to the persistence of cancer stem cells. This challenge may be overcome by AB8939’s dual mechanism of action.

• First, AB8939 blocks the proliferation of leukemia cells through microtubule disruption. It is not subject to multi-drug resistance as it does not bind to PgP, which is responsible for efflux outside the cells, and is not degraded by myeloperoxidase.
  • Second, AB8939 targets leukemia cancer stem cells by inhibiting ALDH and promotes bone marrow repopulation of normal progenitors.

AB8939 + venetoclax combination

There is a strong rationale to combine AB8939 with venetoclax

• Both molecules exhibit low hematologic toxicity. This combination is expected to be less toxic than azacitidine + venetoclax as first-line treatment for AML
• These molecules have different and complementary targets in cancer cells. There is an additive, even synergistic, efficacy potential for the combination, with three mechanisms of action in a single treatment.
  • Venetoclax’s mechanism of action inhibits the BCL2 pathway, a protein that prevents apoptosis (programmed cell death) in cancer cells. BCL2 is a key factor in AML resistance, as it allows cancer cells to survive despite treatment
  • AB8939 is pro-apoptotic, destabilizing microtubules, and would benefit from BCL2 inhibition to optimize apoptosis
  • In addition, AB8939 specifically targets cancer stem cells by inhibiting ALDH, reducing resistance to treatment and limiting the risk of relapse

Next steps

The next step is to complete phase 1 in combination and launch an expansion study in approximately 15 AML patients eligible for AB8939 + venetoclax at the appropriate dose. The expansion phase is expected to generate robust preliminary evidence of efficacy in the AML label, sufficient to support the clinical development plan and a beneficial partnership agreement.

AB Science has started to discuss three possibilities for registration studies, which are not mutually exclusive, with the European Medicines Agency (EMA) and US Food and Drug Administration (FDA):

• AB8939 + venetoclax as first-line treatment, with aged patients and/or patients with adverse genetics (complex karyotypes, TP53 mutations, NRAS and KRAS mutations, monosomy 5 and 7, and MECOM-rearrangement)
• AB8939 + venetoclax as a second- or third-line treatment, in all patients or patients with adverse genetics
• AB8939 as a single agent in MECOM as a second or third-line treatment.

Addressable market with AB8939 in relapsed/refractory AML

Treatments for relapsed or refractory AML represent an estimated market size potential of greater than EUR 2 billion per annum.

EUROPE = EU27 + Norway + United Kingdom + Switzerland ; APAC = Australia, People’s Republic of China , Japan, New Zealand, Singapore, Taiwan ; LATAM = Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico ; MENA = Algeria, Bahrain, Egypt, Israel, Kuwait, Morocco, Oman, Qatar, Saudi Arabia, Tunisia, United Arab Emirates
(1)    Zhou, Y et al. Global, regional, and national burden of acute myeloid leukemia, 1990–2021: a systematic analysis for the global burden of disease study 2021. Biomark Res 12, 101 (2024).
(2)    Ravandi F. Relapsed acute myeloid leukemia: Why is there no standard of care Best Pract Res Clin Haematol. 2013;26(3):253-9
(3)    Walter RB et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia (2015) 29:312–20. .
(4)    Estimated
(5)    Choi M. et al. Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy. Journal of Managed Care & Specialty Pharmacy Volume 28, Number 9. https://doi.org/10.18553/jmcp.2022.22021

Intellectual property

AB8939 intellectual property rights in AML are secured until 2036 through a ‘composition of matter’ patent and potentially until 2041 with a 5 years extension. Two additional ‘second medical use’ patent applications have been filed to protect the use of AB8939 in the treatment of AML with specific chromosomal abnormalities. If these applications are accepted, the protection for AB8939 will be extended until 2044 and 2046 for these AML subpopulations.

AB8939 has also received orphan drug designation for AML by both the EMA and FDA. This orphan drug designation confers 10 and 7 years of marketing exclusivity in Europe and the US, respectively, from the date of product registration.

AB Science is the sole proprietary holder of AB8939 and its family of compounds.

About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment.
AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science’s website:
www.ab-science.com.

Forward-looking Statements – AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend”, “estimate” or “plan” as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

For additional information, please contact:

AB Science
Financial Communication & Media Relations
investors@ab-science.com

Attachment

• CP AB8939 JAN 26 VENG VF

AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia




AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia

PRESS RELEASE

AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA

• The combination treatment was well-tolerated, with no hematological toxicity and no dose limiting toxicity
• The fourth patient had a complex karyotype including a monosomy of chromosome 5 and TP53 mutation, and was in the third-line of treatment. He had a near complete response after 14 days of treatment with AB8939 at 21 mg/m² plus venetoclax
• This is the fourth patient responding to the combination from a total of 4 patients treated
• The partial response rate is 100% (4/4), including one patient in complete remission, one near complete response and 2 partial responses
• The results were obtained after the first cycle of treatment (14 days) in patients receiving third- or fourth-line treatment, two of whom had previously progressed on venetoclax in combination with other chemotherapies
• These four patients all have very difficult to treat cytogenetic profiles, including complex karyotype, TP53 mutation, NRAS mutation, monosomy 5 and MECOM-rearrangement, that typically have a poor prognosis due to their aggressive disease course and treatment resistance
• This diversity of responsive patients appears to corroborate the mechanism of action of AB8939, which is capable of destabilizing microtubules while evading multi-drug resistance and also targeting cancer stem cells without eliminating non tumoral stem cells
• These results corroborate the positioning of AB8939 in patients with adverse genetics, complex karyotypes, TP53 mutations, NRAS and KRAS mutations, monosomy 5 and 7, and MECOM-rearrangement, which represents the highest unmet medical need.

Paris, 07 January 2026, 6pm CET

AB Science SA (Euronext – FR0010557264 – AB) today provides an update on the Phase 1 study of the molecule AB8939 and the fourth consecutive response with the combination of AB8939 + venetoclax in patients with acute myeloid leukemia (AML) associated with a very unfavorable genetic profile.

The fourth patient received AB8939 (21.3 mg/m²) plus venetoclax for 14 days.

The patient had AML with a very negative risk profile,

• complex karyotype including a monosomy of chromosome 5 and also an identified TP53 mutation
• in third-line of treatment, having progressed after CPX-351 treatment and Citarine + Idarrubincine + Fludarabine (3+7) regimen.

Under the AB8939 + venetoclax combination, the patient achieved a partial response.

This fourth result is consistent with the responses previously reported on October 14, 2025, in the first three patients who received AB8939 + venetoclax.

Nicholas J. Short, MD, Associate Professor and Co-Lead of the Section of Developmental Therapeutics, Department of Leukemia, MD Anderson Cancer Center, said, “This new data is very encouraging, particularly considering the very adverse risk profile of this patient’s leukemia. These early efficacy and safety data suggest that AB8939 can be combined with venetoclax and could have significant activity in the highest-risk subtypes of AML. There is a strong interest in continuing the development of this combination in patients whose AML has high-risk features that are expected to lead to resistance to venetoclax + azacitidine.“

Professor Olivier Hermine, MD, President of the Scientific Committee of AB Science and member of the Académie des Sciences in France, said, “There is a strong rationale to combine AB8939 and venetoclax as both molecules have low hematologic toxicity and complementary mode of actions. These first results are supportive of this rationale.”

About AB8939

AB8939 is a drug candidate that targets (i) cancer cells by destabilizing microtubules (essential for cell division) and (ii) cancer stem cells by inhibiting ALDH1A1 and ALDH2 (enzymes essential for maintaining their physiological state and survival).

• AB8939 has shown in vitro activity in Ara-C (cytarabine, which is one of the standards of care) resistant patient cell lines, including adverse genetic MECOM and TP53 mutations.
• Analysis of cell lines responsive to AB8939 showed that AB8939 is effective in cell lines with TP53 mutations, MECOM, and complex karyotypes, whereas ARAC and azacitidine are not effective.
• AB8939 increased survival and had an additive effect in combination with venetoclax (another standard of care) in vivo in a MECOM-grafted PDX mouse model.
• AB8939 increased survival and had an additive effect in combination with Vidaza (azacitidine, another standard of care) in vivo in the MECOM PDX#C1005 mouse model of leukemia.
• AB8939 eradicated Leukemia Cancer Stem Cells in vivo in a human PDX AML mouse model, which is compatible with targeting stem cells via ALDH.

AB8939 is currently being evaluated in a Phase 1 clinical trial (study AB18001, NCT05211570) in patients with refractory and relapsed AML.

The Phase 1 clinical trial of AB8939 has completed its first two stages, which consisted of determining the maximum tolerated dose (MTD) after 3 and 14 consecutive days of monotherapy. In both cases, the MTD was 21.3 mg/m².

The third stage, currently underway, involves evaluating the combination of AB8939 and venetoclax. Three patients were evaluated at the first dose level (AB8939 14 days at a dose of 16 mg/m² + venetoclax 14 days). The current dose level evaluates (AB8939 14 days at a dose of 21.3 mg/m² + venetoclax 14 days)

Medical need in AML and AB8939 mechanism of action

Although several drugs have been registered for AML, 70% of patients still relapse and die, creating a persistent unmet medical need for effective treatments. Acute myeloid leukemia remains the most lethal form of leukemia in humans.

AML is a heterogeneous disease, and its outcome is highly dependent on genetic factors. TP53 mutation has a very poor prognosis, with a median overall survival (OS) of 5.5 months. NRAS and KRAS mutants have a poor prognosis, with a median OS of 12.1 months. MECOM also has a very poor prognosis in AML, with a median OS of 5.5 months in relapsed or refractory settings.

The challenge in AML is the recurrence of tumors due to a combination of two factors: the resistance of cancer cells to chemotherapy and relapse due to the persistence of cancer stem cells. This challenge may be overcome by AB8939’s dual mechanism of action.

• First, AB8939 blocks the proliferation of leukemia cells through microtubule disruption. It is not subject to multi-drug resistance as it does not bind to PgP, which is responsible for efflux outside the cells, and is not degraded by myeloperoxidase.
  • Second, AB8939 targets leukemia cancer stem cells by inhibiting ALDH and promotes bone marrow repopulation of normal progenitors.

AB8939 + venetoclax combination

There is a strong rationale to combine AB8939 with venetoclax

• Both molecules exhibit low hematologic toxicity. This combination is expected to be less toxic than azacitidine + venetoclax as first-line treatment for AML
• These molecules have different and complementary targets in cancer cells. There is an additive, even synergistic, efficacy potential for the combination, with three mechanisms of action in a single treatment.
  • Venetoclax’s mechanism of action inhibits the BCL2 pathway, a protein that prevents apoptosis (programmed cell death) in cancer cells. BCL2 is a key factor in AML resistance, as it allows cancer cells to survive despite treatment
  • AB8939 is pro-apoptotic, destabilizing microtubules, and would benefit from BCL2 inhibition to optimize apoptosis
  • In addition, AB8939 specifically targets cancer stem cells by inhibiting ALDH, reducing resistance to treatment and limiting the risk of relapse

Next steps

The next step is to complete phase 1 in combination and launch an expansion study in approximately 15 AML patients eligible for AB8939 + venetoclax at the appropriate dose. The expansion phase is expected to generate robust preliminary evidence of efficacy in the AML label, sufficient to support the clinical development plan and a beneficial partnership agreement.

AB Science has started to discuss three possibilities for registration studies, which are not mutually exclusive, with the European Medicines Agency (EMA) and US Food and Drug Administration (FDA):

• AB8939 + venetoclax as first-line treatment, with aged patients and/or patients with adverse genetics (complex karyotypes, TP53 mutations, NRAS and KRAS mutations, monosomy 5 and 7, and MECOM-rearrangement)
• AB8939 + venetoclax as a second- or third-line treatment, in all patients or patients with adverse genetics
• AB8939 as a single agent in MECOM as a second or third-line treatment.

Addressable market with AB8939 in relapsed/refractory AML

Treatments for relapsed or refractory AML represent an estimated market size potential of greater than EUR 2 billion per annum.

EUROPE = EU27 + Norway + United Kingdom + Switzerland ; APAC = Australia, People’s Republic of China , Japan, New Zealand, Singapore, Taiwan ; LATAM = Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico ; MENA = Algeria, Bahrain, Egypt, Israel, Kuwait, Morocco, Oman, Qatar, Saudi Arabia, Tunisia, United Arab Emirates
(1)    Zhou, Y et al. Global, regional, and national burden of acute myeloid leukemia, 1990–2021: a systematic analysis for the global burden of disease study 2021. Biomark Res 12, 101 (2024).
(2)    Ravandi F. Relapsed acute myeloid leukemia: Why is there no standard of care Best Pract Res Clin Haematol. 2013;26(3):253-9
(3)    Walter RB et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia (2015) 29:312–20. .
(4)    Estimated
(5)    Choi M. et al. Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy. Journal of Managed Care & Specialty Pharmacy Volume 28, Number 9. https://doi.org/10.18553/jmcp.2022.22021

Intellectual property

AB8939 intellectual property rights in AML are secured until 2036 through a ‘composition of matter’ patent and potentially until 2041 with a 5 years extension. Two additional ‘second medical use’ patent applications have been filed to protect the use of AB8939 in the treatment of AML with specific chromosomal abnormalities. If these applications are accepted, the protection for AB8939 will be extended until 2044 and 2046 for these AML subpopulations.

AB8939 has also received orphan drug designation for AML by both the EMA and FDA. This orphan drug designation confers 10 and 7 years of marketing exclusivity in Europe and the US, respectively, from the date of product registration.

AB Science is the sole proprietary holder of AB8939 and its family of compounds.

About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment.
AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science’s website:
www.ab-science.com.

Forward-looking Statements – AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend”, “estimate” or “plan” as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

For additional information, please contact:

AB Science
Financial Communication & Media Relations
investors@ab-science.com

Attachment

• CP AB8939 JAN 26 VENG VF

Comprehensive Healthcare Welcomes Community Behavioral Health Veteran as Chief Medical Officer




Comprehensive Healthcare Welcomes Community Behavioral Health Veteran as Chief Medical Officer

YAKIMA, Wash., Jan. 07, 2026 (GLOBE NEWSWIRE) — Comprehensive Healthcare, the leading community behavioral health provider in Central and Southwest Washington, is proud to welcome Mark Bradshaw, M.D., as its new chief medical officer (CMO). In this role, Dr. Bradshaw will oversee Comprehensive Healthcare’s continuum of clinical programs and services and a growing team of dedicated professionals working to expand access to high-quality, integrated care.

“Comprehensive Healthcare is at a pivotal moment in its growth. We’re introducing new programs, expanding our facilities and making meaningful progress toward realizing the full promise of an innovative approach to care that’s responsive to local needs, and we’re excited to have Dr. Bradshaw at the helm,” said Jodi Daly, Ph.D., CEO of Comprehensive Healthcare. “Dr. Bradshaw brings the expertise and passion we need to guide this next chapter, keeping our focus on the people and communities we’re here to serve.”

A key priority for Dr. Bradshaw will be advancing implementation of the Certified Community Behavioral Health Clinic (CCBHC) model as part of Washington’s first CCBHC Pre-Certification Cohort. He will partner with clinical and operational teams to strengthen care coordination, enhance access to services and refine systems that support whole-person health.

In addition, Dr. Bradshaw will focus on expanding the organization’s continuum of mental health and substance use services, building on the success of recent initiatives that streamline care and improve client engagement, such as the opening of the Wellness Now Clinic in Yakima and the introduction of same-day substance use disorder (SUD) assessments.

“Comprehensive Healthcare immediately stood out to me for its commitment to the community and the wide range of services it offers,” said Dr. Bradshaw. “It’s clear that the team at Comprehensive Healthcare approaches their work with genuine care and energy. I’m honored to join an organization so deeply invested in improving the lives of those it serves.”

Dr. Bradshaw joins Comprehensive Healthcare after serving as the chief medical officer at Elevance Health and Georgia Collaborative ASO, a community behavioral health provider that delivers care to underserved individuals through grant-funded programs. His decades-long career also includes serving as CMO for a Coordinated Care Organization in Southern Oregon, in addition to leadership and psychiatric positions across a range of mental health agencies.

Throughout his career, Dr. Bradshaw has been recognized for his excellent clinical service and has shared his expertise with the next generation of providers through teaching. He has taught as an adjunct faculty member at Wright State University and the University of Cincinnati College of Medicine and has served on numerous healthcare boards and advisory committees. Dr. Bradshaw earned his Doctor of Medicine degree from the University of Mississippi School of Medicine.

For more information about Comprehensive Healthcare, visit https://comphc.org/.

About Comprehensive Healthcare: 
As one of largest behavioral health organizations in the state of Washington, Comprehensive Healthcare serves clients in the Greater Columbia Region. Comprehensive Healthcare is a Joint Commission accredited organization, providing compassionate, individualized behavioral healthcare since 1972. As a non-profit organization, Comprehensive Healthcare is dedicated to delivering high quality, evidence-based services to individuals, families and organizations. To learn more, visit Comprehensive Healthcare’s website at comphc.org.

Media Contacts: 
Cassidy Brown 
Comprehensive Healthcare 
(509) 317-2876 
cassidy.brown@comphc.org 

Kate Hughes 
Firmani + Associates
kate@firmani.com

GENFIT Announces 2026 Financial Calendar




GENFIT Announces 2026 Financial Calendar

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026 – GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026.

2026 Financial Calendar

This calendar is subject to change.

ABOUT GENFIT

GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades.  

Today, GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow.

GENFIT’s expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for the treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.¹   

Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis).

GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT). In 2021, Ipsen became one of GENFIT’s largest shareholders, acquiring an 8% stake in the Company’s capital. www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements about GENFIT’s expected progress of its research and development programs and planned release of financial information. The use of certain words, such as “believe”, “potential”, “expect”, “target”, “may”, “will”, “should”, “could”, “if” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to non-clinical and pre-clinical programs, reproducibility of preclinical results, the translation of animal model data to human biology, in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Risk Factors and Internal Control” of the Company’s 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers (“AMF”), which is available on GENFIT’s website (www.genfit.com) and the AMF’s website (bdif.amf-france.org), and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s 2024 Annual Report on Form 20-F filed with the SEC on April 29, 2025 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACTS

GENFIT | Investors

Tel: +33 3 2016 4000 | investors@genfit.com

GENFIT | Media

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | +333 2016 4000 | www.genfit.com       

1 Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo® .

Attachment

• GENFIT Announces 2026 Financial Calendar

National Institutes of Health Awards $1.54M Grant To Scottish Rite for Children for Rare Diseases Research




National Institutes of Health Awards $1.54M Grant To Scottish Rite for Children for Rare Diseases Research

Promising Hydrogel Could Help Kids Walk Again and Adults Avoid Invasive Surgery

Dallas, Jan. 07, 2026 (GLOBE NEWSWIRE) — Every year, thousands of children and adults face the crippling effects of osteonecrosis. Now, thanks to a $1.54 million NIH grant, researchers at Scottish Rite for Children and UT Southwestern Medical Center are studying a promising new treatment using hydrogel. Osteonecrosis is a painful condition where reduced blood flow causes bone tissue to die, which leads to the bone collapsing. For children, the condition often appears as Legg-Calvé-Perthes disease, a hip disorder that can leave young patients limping or even unable to walk.

The study’s goal is to evaluate the treatment effectiveness of a pro-angiogenic bone coating (ABC) hydrogel, which is injected into the bone experiencing osteonecrosis. The gel is made mostly from natural ingredients, like gelatin and hyaluronic acid, and is designed to promote the growth of new blood vessels and support the healing and regeneration of damaged bone.

“The hydrogel works like a ‘smart glue.’ When it is injected into the injured bone, it quickly breaks down and clings to the bone where it is needed most,” says Chi Ma, Ph.D., senior research scientist at Scottish Rite for Children and assistant professor of orthopedic surgery at UT Southwestern. “This helps restore blood flow, stops the bone from breaking down further, and encourages the bone to heal, leading to a less invasive method for treating the progressive condition.”

According to the National Organization for Rare Diseases, osteonecrosis affects an estimated 20,000 people in the U.S. each year, including children, young adults and individuals undergoing treatments such as chemotherapy. In serious cases, the affected bone, often in the hip or knee, may collapse, making walking intolerable. Current treatments are limited and often involve invasive surgery or joint replacement, especially in advanced stages of the disease.

The hydrogel is designed to have unique features that make it a candidate for better treatment for osteonecrosis.

“Conducting groundbreaking research is a pillar of our institution,” says Scottish Rite for Children Chief of Staff Daniel J. Sucato, M.D., M.S. “We’ve had a relationship with UT Southwestern since 1948, and we’re grateful for this ongoing collaboration that allows us to focus on discovering new treatments, educating the next generation in pediatric orthopedics and providing the highest quality patient care.”

The ABC hydrogel as a treatment for osteonecrosis may offer hope not only for adults affected by the condition but also for children with Perthes disease. Perthes disease is a childhood hip disorder in which the blood supply to the ball of the hip’s ball-and-socket joint is temporarily cut off. This disruption causes all or part of the bone to die. As the condition progresses, the ball begins to collapse. A child with Perthes may begin limping and eventually, may be unable to walk. This treatment aims to preserve the rounded shape that fits into the socket of the hip joint and reverse the progression of the disease for full recovery.

“At Scottish Rite for Children, we are dedicated to transforming the lives of children and their families by turning our research discoveries into meaningful treatments and life-changing outcomes,” says Robert L. Walker, president/CEO of Scottish Rite.

About Scottish Rite for Children 
Scottish Rite for Children has been dedicated to giving children back their childhood for more than a century. The institution is a world-renowned leader in the treatment of pediatric orthopedic conditions, such as scoliosis, clubfoot, hand differences, hip disorders, limb lengthening and reconstruction, sports injuries and fractures, as well as certain related arthritic and neurological disorders and learning disorders, such as dyslexia. The organization conducts innovative research and provides high-level education opportunities for medical professionals around the world. Scottish Rite operates two campuses, including a hospital in Dallas, Texas, and an ambulatory surgery center in Frisco, Texas, and is known for being a bright, child-friendly place that does not look or feel like a health care institution. Patients receive treatment regardless of their family’s ability to pay. For more information about services available at the Dallas or Frisco campuses, volunteering or donating, visit scottishriteforchildren.org.

Contact Info

Liandra Larsen
Liandra.Larsen@tsrh.org
+1 469-929-4891

Attachment

• National Institutes of Health Awards $1.54M Grant To Scottish Rite for Children for Rare Diseases Research

Neocis Surpasses 100,000 Robotic Osteotomies with the Yomi Platform




Neocis Surpasses 100,000 Robotic Osteotomies with the Yomi Platform

Landmark milestone demonstrates proven robotic adoption as the next generation Yomi S completes the first real world cases

MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) — Neocis, the market leader behind the Yomi® robotic dental implant system, today announced that clinicians have completed more than 100,000 osteotomies using the Yomi platform, marking a significant milestone in the real-world adoption of robotic assistance in implant dentistry.

Neocis also confirmed that the first clinical cases using Yomi S, its second-generation robotic system, have now been successfully completed by Dr. Jay Neugarten, DDS, MD, FACS. The initial procedures signal the new platform’s transition to clinical reality, reinforcing Neocis’ ability to translate innovation into deployable technology while building on the proven foundation established by more than 100,000 Yomi-guided osteotomies.

The achievement reflects sustained clinical use of Yomi across a broad range of implant indications and practice settings, underscoring the platform’s role in supporting precision, consistency, and confidence during dental implant surgeries.

“Reaching 100,000 osteotomies is more than just a statistical achievement — it represents clinicians across the country choosing to integrate robotics into their daily surgical workflow,” said Alon Mozes, Chief Executive Officer and co-founder of Neocis. “This level of usage demonstrates trust in the technology and reinforces our belief that robotics has set a new standard of care.”

Yomi is the first and only FDA-cleared robotic system for dental implant surgery, and Yomi S was recently announced in 2025 as the second generation system. The platform combines real-time haptic guidance, pre-operative digital planning, and intra-operative adaptability to assist clinicians during implant cases. Since its introduction, Yomi has been used in a wide variety of cases, from single-tooth to full-arch implant procedures.

“Clinicians are increasingly seeking technologies that integrate seamlessly into existing workflows while delivering tangible procedural value,” said Dennis Moses, Chief Technology Officer of Neocis. “The scale reflected in 100,000 osteotomies validates both the robustness of the platform and its proven ability to perform consistently across real-world clinical environments.”

Neocis continues to invest in expanding Yomi’s capabilities through software enhancements, workflow optimization, and advanced planning tools designed to support efficient case execution and broaden clinical applications.

The 100,000-osteotomy milestone represents another step forward in Neocis’ mission to advance robotic innovation in dentistry and support clinicians everywhere in delivering high-quality implant care.

About Neocis
Neocis is transforming dental surgery with robotics. The company collaborates closely with leading clinicians to develop innovative technologies that help advance patient care and improve quality of life. Based in Miami, Neocis is venture-backed with funding from Mirae Asset Financial Group, NVentures, Intuitive Ventures, DFJ Growth, Mithril Capital Management, Norwest Venture Partners, Vivo Capital, Section 32, and surgical robotics pioneer Fred Moll. For more information, visit neocis.com.

Contact
For more information, please contact the Neocis media relations team at info@neocis.com.

Vaxxas Appoints Former Merck Global Vaccines President David Peacock as CEO




Vaxxas Appoints Former Merck Global Vaccines President David Peacock as CEO

BRISBANE, Australia and CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) — Vaxxas Pty Ltd today announced the appointment of global biopharmaceutical executive Mr David Peacock as Chief Executive Officer to lead the commercialisation of the Company’s proprietary high‑density microarray patch (HD‑MAP) vaccination technology.

Mr Peacock brings more than 25 years of global vaccine and pharmaceutical leadership, most recently in roles as President of Merck Global Vaccines, and President of MSD Asia Pacific.

His career spans senior commercial, operational, and financial positions across Japan, the United States, Europe, and Asia, and includes service on boards and industry bodies such as the US‑ASEAN Business Council, the Association of the British Pharmaceutical Industry, and Gavi, the Vaccine Alliance.

Throughout his career Mr Peacock has demonstrated strong entrepreneurial and innovation success through start-ups, digital commercial innovation and funding access initiatives.

Vaxxas Chair, Ms Sarah Meibusch said Mr Peacock’s appointment aligns with the company’s near‑term pathway to market and growth strategy.

“David’s appointment marks a clear inflection point for Vaxxas as we move from clinical validation towards commercial execution. He brings unmatched global vaccine commercialisation experience at precisely the moment the HD-MAP technology is transitioning from proof-of-concept to a scalable delivery platform with the potential to materially improve how vaccines are manufactured, distributed and administered worldwide.

“For global pharmaceutical partners, the HD-MAP offers a differentiated self-delivery administration option to enhance existing vaccine franchises, extend lifecycle value and address persistent challenges around cold-chain, dose efficiency and access. David’s leadership positions Vaxxas to engage at scale with governments and multinational vaccine companies as a long-term strategic partner,” said Ms Meibusch.

Mr Peacock said he is energised by the potential of Vaxxas’ HD‑MAP technology to reshape vaccine delivery and access.

“Over the course of my career, I have seen first-hand the limitations of conventional vaccine delivery technologies in both developed, and developing, healthcare systems. I believe Vaxxas’ HD-MAP technology has the potential to fundamentally reshape vaccine access, distribution, and administration.

“Vaxxas is now at a pivotal stage, with clinical validation, licensed manufacturing capability and a platform that can integrate with existing and future vaccine programs. I am excited to lead the company as we partner with pharmaceutical companies, research organisations and governments to translate this technology for global public-health and commercial impact,” said Mr Peacock.

Mr Peacock will also be appointed as Executive Director to the Vaxxas board.

Building Momentum Toward Market

Vaxxas recently secured a manufacturing licence from the Therapeutic Goods Administration (TGA), for HD‑MAP vaccine products at the company’s Brisbane biomedical facility, a significant regulatory milestone that materially de-risks the path to commercial supply. The licence follows the installation of Vaxxas’ first robotic lines for aseptic (sterile) manufacture, enabling scalable, GMP-compliant production to support clinical and future commercial programs.

Mr Peacock’s appointment also follows recent board and leadership additions, most notably global vaccine industry veteran Brent MacGregor, CEO of Medical Developments International (ASX: MVP), who has more than 30 years of senior commercial leadership across the global vaccines sector. Mr MacGregor has held leadership roles at CSL Seqirus, Novartis Vaccines and Sanofi Pasteur across North America, Europe and Asia, and brings deep experience in vaccine commercialisation and scale. He is complemented by Michael Shleifer, Co-Founder and Managing Partner of SPRIM Global Investments, which anchored Vaxxas’ approximately $90 million financing this year, joining as Board Observer.

“Together, these appointments provide Vaxxas significant depth in global vaccine commercialisation, manufacturing and partnership expertise. This strengthens Vaxxas’ ability to work credibly with multinational pharmaceutical companies and governments as the HD-MAP technology advances toward scaled manufacture and broader deployment,” Ms Meibusch added.

About Vaxxas
Vaxxas is a biotechnology company pioneering HD-MAP technology for future self-administered vaccine delivery. The HD-MAP has been administered to more than 750 participants across clinical trials, demonstrating strong safety, tolerability, and robust immune responses. Preclinical and clinical data indicate the technology has the potential to deliver all major vaccine types positioning HD-MAP as a universal delivery solution. By targeting immune cells just beneath the skin, the HD-MAP has the potential to achieve stronger protection with smaller doses, while reducing cold-chain requirements and enabling self-administration.

Vaxxas’ programs are advancing toward commercialisation with support from global partners including SK bioscience, the US Government, the Wellcome Trust, and the Gates Foundation, assessing the potential of HD‑MAP to vaccinate against COVID‑19, seasonal and pre‑pandemic influenza, and measles and rubella. The company recently installed robotic lines for aseptic (sterile) manufacture at its state‑of‑the‑art Brisbane biomedical facility supporting scalable, GMP-compliant production for clinical and future commercial supply.

Investigational Use Notice
HD‑MAP‑delivered vaccines are under investigation and are not approved for sale or purchase anywhere in the world. Vaxxas makes no claims regarding reliability, durability, dependability, safety, efficacy, or superiority to any other vaccine or vaccine delivery technology.

A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/6b1ec1d5-e7a0-42cd-a707-66acc4905ff5
https://www.globenewswire.com/NewsRoom/AttachmentNg/1b38e870-00e0-4868-bc1b-05f0f5f868c8
https://www.globenewswire.com/NewsRoom/AttachmentNg/9364912a-9e89-446f-8ca7-c7649830e517

CONTACT: Media Contact
Helen Wallace
We. Communications
+61 310 710 305
hwallace@wecommunications.com

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts




Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity–

– Verrica has global rights to YCANTH for all indications in all territories outside of Japan –

WEST CHESTER, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that the first patient was dosed in December 2025 in the global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts.

“The dosing of the first patient in the global Phase 3 program in common warts represents an important clinical milestone for our label expansion strategy of YCANTH,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “The clinically meaningful activity observed for the primary endpoint of complete clearance in the Phase 2 COVE-1 study provides strong evidence that YCANTH has the potential to become the first therapy ever approved in both the United States and Japan for the treatment of common warts – a condition that impacts over 22 million people in the U.S. alone. Having retained full commercial rights for all potential YCANTH indications outside of Japan, common warts represents a substantial commercial and licensing opportunity for our company. Coupled with our recently completed $50 million financing and repayment of our debt facility with OrbiMed, this significant clinical milestone is another key step towards the expansion of the YCANTH franchise and the future growth of Verrica.”

COVE-1 Phase 2 Data and Phase 3 Program in Common Warts

The initiation of the global Phase 3 program in common warts is based upon positive results from the Phase 2 COVE-1 clinical trial that evaluated YCANTH (VP-102) for the treatment of common warts. COVE-1 was an open label clinical trial that evaluated the safety and efficacy of VP-102 in two cohorts of subjects with up to six warts. The primary efficacy analysis was conducted at Day 84 with an additional period of follow-up through Day 147. Topline analysis included data from the assessment of warts at study visits over 12 weeks. Results showed that 51% of subjects (18 of 35) treated with VP-102 in Cohort 2 achieved complete clearance of all treatable warts at Day 84. Adverse events were primarily expected local cutaneous reactions with no SAEs observed. Torii will split the costs of the global Phase 3 program with Verrica on a 50/50 basis and will fund the first $40 million of trial costs, representing approximately 90% of the current trial budget, with Verrica’s portion expected to be paid out of future milestones/royalties for YCANTH in Japan.

Market Opportunity in Common Warts

With a prevalence of approximately 22 million patients in the U.S. alone and no FDA approved therapies, common warts represent one of the largest unmet needs in all of dermatology, which Verrica believes could represent a multibillion-dollar commercial opportunity. In the United States, approximately 50% of the patients who seek treatment for common warts are children. If YCANTH is successfully developed, approved and commercialized for the treatment of common warts, Verrica anticipates a high degree of call point overlap and marketing synergies with its promotion of YCANTH for the treatment of molluscum. Verrica further believes that the common wart patient opportunity in the European Union is comparable to that in the United States.

About YCANTH^® (VP-102)
YCANTH^® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of YCANTH was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH was a safe and effective therapeutic for the treatment of molluscum. Approximately 250 million lives are eligible to receive YCANTH covered by insurance. Commercially insured patients pay just $25 per YCANTH treatment visit, for up to two applicators. Other uninsured patients may be eligible to receive YCANTH at a reduced cost if certain eligibility requirements are met for patient assistance. Please visit YCANTHPro.com for additional information.

About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH^® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH^® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about the commercialization of YCANTH, clinical development, clinical timelines and potential benefits of YCANTH for the treatment of common warts, These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions, satisfaction of customary closing conditions related to the proposed public offering and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2024, Verrica’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

John Kirby
Interim Chief Financial Officer
jkirby@verrica.com

Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com